Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
Siegfried SegaertDepartment of Dermatology, University Hospital Leuven, BelgiumAbstract: Etanercept, a subcutaneously administered fully human soluble tumor necrosis factor (TNF) receptor, was initially approved for the treatment of psoriasis at a dose of 25 mg twice weekly in repeated 24-week cycle...
Saved in:
| Main Author: | |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2009
|
| Subjects: | |
| Online Access: | https://doaj.org/article/c3a4606f391a49e58df829dbcf40fbc6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|